CTLA-4 +49A/G Polymorphism Increases the Susceptibility to Bladder Cancer in Chinese Han Participants: A Case-Control Study

Table 4

The associations between CTLA-4 +49A/G polymorphism and clinical characteristics of bladder cancer.

Characteristics	Genotype distributions
	AA	AG	GG
Tumor grade
High/low	139/67	77/50	11/10	88/60
OR (95% CI); value	1.00 (reference)	0.74 (0.47-1.18); 0.204	0.53 (0.22-1.31); 0.164	0.71 (0.46-1.10); 0.121
Tumor size
≥3/<3	42/164	39/88	11/10	50/98
OR (95% CI); value	1.00 (reference)	1.73 (1.04-2.87); 0.033	4.30 (1.71-10.79); 0.001	1.99 (1.23-3.22); 0.005
TNM stage
/	96/110	70/57	11/10	81/67
OR (95% CI); value	1.00 (reference)	1.41 (0.90-2.19); 0.131	1.26 (0.51-3.10); 0.613	1.39 (0.90-2.12); 0.131
Tumor node metastasis
Yes/no	55/151	41/86	12/9	53/95
OR (95% CI); value	1.00 (reference)	1.31 (0.81-2.12); 0.274	3.66 (1.46-9.17); 0.004	1.53 (0.97-2.42); 0.066
Distant metastasis
M1/M0	12/194	8/119	3/18	11/137
OR (95% CI); value	1.00 (reference)	1.09 (0.43-2.74); 0.860	2.69 (0.70-10.44); 0.137	1.30 (0.56-3.03); 0.545
Histology
Papillary/nonpapillary	166/40	106/21	19/2	125/23
OR (95% CI); value	1.00 (reference)	1.22 (0.68-2.18); 0.509	2.29 (0.51-10.23); 0.414	1.31 (0.75-2.30); 0.347

Bold values are statistically significant ().